Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Common Equity (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Common Equity for 7 consecutive years, with $381.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 5.63% to $381.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $381.0 million through Dec 2025, up 5.63% year-over-year, with the annual reading at $381.0 million for FY2025, 5.63% up from the prior year.
  • Common Equity hit $381.0 million in Q4 2025 for Immunocore Holdings, down from $396.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $396.6 million in Q3 2025 to a low of $231.2 million in Q4 2021.
  • Historically, Common Equity has averaged $355.5 million across 5 years, with a median of $360.1 million in 2024.
  • Biggest five-year swings in Common Equity: skyrocketed 216.42% in 2021 and later dropped 2.2% in 2024.
  • Year by year, Common Equity stood at $231.2 million in 2021, then soared by 41.39% to $327.0 million in 2022, then rose by 12.81% to $368.8 million in 2023, then decreased by 2.2% to $360.7 million in 2024, then rose by 5.63% to $381.0 million in 2025.
  • Business Quant data shows Common Equity for IMCR at $381.0 million in Q4 2025, $396.6 million in Q3 2025, and $388.5 million in Q2 2025.